Vasopressin: A new target for the treatment of heart failure

American Heart Journal

Volumn 146, Issue 1, 2003, Pages 9-18

  Lee, Craig R ^a   Watkins, Michael L ^e   Patterson, J Herbert ^a,b   Gattis, Wendy ^c   O'Connor, Christopher M ^c   Gheorghiade, Mihai ^d   Adams Jr , Kirkwood F ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONIVAPTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LIXIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; NORADRENALIN; SODIUM; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

BLOOD VESSEL TONE; BODY FLUID; BODY WATER; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE CONTRACTILE FORCE; HEART OUTPUT; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HEMODYNAMICS; HOMEOSTASIS; HORMONE SYNTHESIS; HUMAN; HYPONATREMIA; LUNG CAPILLARY PRESSURE; NONHUMAN; PHYSIOLOGY; PLASMA OSMOLALITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SYMPTOM; SYSTEMIC VASCULAR RESISTANCE; URINARY EXCRETION;

EID: 0037823130     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(02)94708-3     Document Type: Article

References (51)

1. Schrier RW, Abraham W. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85.
2. Heart Failure Society of America. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail 1999;5: 357-82.
3. Penit J, Faure M, Jard S. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. Am J Physiol 1983; 244:E72-82.
4. 1a vasopressin receptor. J Biol Chem 1994;269:3304-10.
5. Nielsen S, Kwon TH, Christensen BM, et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999;10:647-63.
6. Guyton AC. The kidneys and body fluids. In: Guyton AC, Hall JE, editors. Textbook of Medical Physiology. Philadelphia: WB Saunders Company; 1996. p. 308-72.
7. Goldsmith SR. Vasopressin as vasopressor. Am J Med 1987;82: 1213-19.
8. Ebert TJ, Cowley AW, Skelton M. Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. J Clin Invest 1986;77:1136-42.
9. 2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats. Am J Physiol 1999;276:R872-9.
10. Khayyal MA, Eng C, Franzen D, et al. Effects of vasopressin on the coronary circulation: reserve and regulation during ischemia. Am J Physiol 1985;248:H516-22.
11. 2-vasopressinergic receptors. Am J Physiol 1988;255:H261-5.
12. Fujisawa S, Iijima T. On the inotropic actions of arginine vasopressin in ventricular muscle of the guinea pig heart. Jpn J Pharmacol 1999;81:309-12.
13. Goldsmith SR, Francis GS, Cowley AW, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983;1:1385-90.
14. Szatalowicz VL, Arnold PE, Chaimovitz C, et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-6.
15. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82: 1724-9.
16. Goldsmith SR, Francis GS, Cowley AW. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 1986;58:295-9.
17. Schrier RW, Martin PY. Recent advances in the understanding of water metabolism in heart failure. Adv Exp Med Biol 1998;449: 415-26.
18. Xu DL, Martin PY, Ohara M, et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 1997;99:1500-5.
19. Chin MH, Goldman L. Correlates of major complications or death in patients admitted ta the hospital with congestive heart failure. Arch Intern Med 1996;156:1814-20.
20. Goldsmith SR, Francis GS, Cowley AW, et al. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 1986;8:779-83.
21. Tahara A, Tomura Y, Wada K, et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 1998;38: 198-205.
22. 1A receptor. Eur J Pharmacol 2000;391:39-48.
23. 1 receptor. Mol Cell Biochem 1999;195:93-8.
24. 1a receptor antagonist [abstract]. Circulation 2001;104(2 Suppl):186.
25. i and protein kinase C in vasopressin-induced prostacyclin and ANP release in rat cardiomyocytes. Am J Physiol 1994;266:H597-605 [Ca2+].
26. Shoji M, Kimura T, Matsui K, et al. Role of intracerebral angiotensin receptors in the regulation of vasopressin release and the cardiovascular system. Neuroendocrinology 1986;43:239-44.
27. Yamamoto T, Kimura T, Ota K, et al. Central effects of endothelin-1 on vasopressin release, blood pressure, and renal solute excretion. Am J Physiol 1992;262:E856-62.
28. Creager MA, Faxon DP, Cutler SS, et al. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 1986;7:758-65.
29. Clair MJ, King MK, Goldberg AT, et al. Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. J Pharmacol Exp Ther 2000;293:852-60.
30. Nicod P, Waeber B, Bussien JP, et al. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol 1985;55:1043-7.
31. 2 antagonist in men. J Pharmacol Exp Ther 1995;272:546-51.
32. 2 antagonist OPC-31260 in heart failure in the rat. Am J Physiol 1998;275:H176-82.
33. 2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998;287:860-7.
34. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000; 292:288-94.
35. Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994;267:H2245-54.
36. 2 receptor antagonist. J Clin Invest 1996;98:2729-38.
37. Gheorghiade M, Niazi I, Ouyang J, et al. Chronic effects of vasopressin receptor blockade with tolvaptan in congestive heart failure: a randomized, double-blind trial [abstract]. Circulation 2000; 102(2 Suppl):592.
38. Gheorghiade M, Konstam MA, Udelson JE, et al. Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients [abstract]. J Am Coll Cardiol 2002;39(5 Suppl A):171A.
39. Udelson JE, O'Brien T, Sequeira R, et al. Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination [abstract]. J Am Coll Cardiol 2002;39(5 suppl A):156A.
40. 2 receptor blockade versus fluid restriction in the treatment of hyponatremia: results from a multicenter randomized controlled trial [abstract]. Circulation 2001;104(2 Suppl):438.
41. 2 receptor antagonist. Adv Exp Med Biol 1998;449:439-43.
42. 2 receptor vasopressin antagonist in patients with chronic heart failure [abstract]. J Am Coll Cardiol 1997;29(2 Suppl A):169A.
43. 2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999;10: 2165-70.
44. Serradeil-Le Gal C. An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist. Cardiovasc Drug Rev 2001;19:201-14.
45. 2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1997;282:301-8.
46. 2 receptor antagonist, in dogs. Eur J Pharmacol 1997;321:225-30.
47. 2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 1999;376:239-46.
48. 2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 1999;55:633-7.
49. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104:2417-23.
50. 2 receptor antagonist, in patients with NYHA class III/IV heart failure [abstract]. Circulation 2000;102(2 Suppl):535.
51. 2 receptor antagonist, reduces pulmonary capillary wedge pressure independent of base-line serum sodium or vasopressin levels in heart failure patients [abstract]. J Am Coll Cardiol 2001;37(2 suppl A):172-3A.